Promising Outlook for EyePoint Pharmaceuticals with Duravyu’s Potential Impact on Wet AMD Treatment

Debanjana Chatterjee, an analyst from JonesTrading, maintained the Buy rating on EyePoint Pharmaceuticals. The associated price target remains the same with $43.00.Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow. Debanjana Chatterjee’s rating is based on the promising outlook for EyePoint Pharmaceuticals, particularly with its upcoming wet AMD therapy, Duravyu. The pivotal data expected in 2026 suggests that Duravyu could significantly impact the treatment landscape, offering a durable solution in a competitive field. The company’s strategic approach to regulatory approval for wet AMD therapies further strengthens its position, potentially reducing associated risks compared to other innovative trial designs. Additionally, the anticipated clinical trials and readouts in 2026, including the LUGANO and LUCIA trials, are expected to provide critical insights into Duravyu’s efficacy and positioning against existing treatments. The financial health of EyePoint Pharmaceuticals, with substantial cash reserves, also supports its ability to advance these programs effectively, making it an attractive investment opportunity in the healthcare sector. Chatterjee covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Opus Genetics, and KalVista Pharmaceuticals. According to TipRanks, Chatterjee has an average return of 31.8% and a 64.13% success rate on recommended stocks. In another report released on November 10, Mizuho Securities also reiterated a Buy rating on the stock with a $33.00 price target.